IMUX

+ Watchlist + Portfolio

Immunic, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $16.45
52-Week Range: $5.06 – $17.43
Market Cap: $219.68M
P/E (TTM): —
EPS (TTM): -3.46
Dividend Yield: —

Advanced Metrics

Price/Book: 1.45
PEG Ratio: —
Return on Equity: -138.17%
Return on Assets: -66.80%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 5.05
Debt/Equity: 0.00
Total Debt: $567.00K
Free Cash Flow: $-51.41M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $65.14M

IMUX Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$71.25M	$83.22M	$80.05M	$81.98M
Selling, General & Admin	$15.26M	$16.01M	$18.01M	$21.25M
Operating Expenses	$86.52M	$99.22M	$98.05M	$103.23M
Operating Income	-$86.52M	-$99.22M	-$98.05M	-$103.23M
EBITDA	-$86.44M	-$99.11M	-$97.92M	-$103.06M
Pretax Income	-$120.41M	-$93.61M	-$100.51M	-$97.17M
Net Income	-$120.41M	-$93.61M	-$100.51M	-$97.17M
Diluted EPS	-37.80	-21.10	-10.00	-6.20
Diluted Shares	3.18M	4.43M	10.02M	15.57M

IMUX Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$106.75M	$46.67M	$35.67M	$15.48M
Receivables	$2.66M	$2.48M	$684.00K	$4.12M
Current Assets	$125.86M	$52.53M	$39.33M	$22.87M
Total Assets	$127.75M	$54.30M	$40.87M	$24.05M
Current Liabilities	$13.08M	$24.73M	$22.18M	$30.62M
Total Debt	$1.56M	$1.33M	$1.00M	$577.00K
Total Liabilities	$14.07M	$25.37M	$22.44M	$30.73M
Retained Earnings	-$317.28M	-$410.89M	-$511.40M	-$608.57M
Shareholders' Equity	$113.68M	$28.93M	$18.43M	-$6.67M
Working Capital	$112.79M	$27.80M	$17.16M	-$7.75M

IMUX Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$65.14M	-$70.83M	-$84.77M	-$85.81M
Capital Expenditure	-$112.00K	-$334.00K	-$264.00K	-$161.00K
Free Cash Flow	-$65.26M	-$71.16M	-$85.03M	-$85.97M
Depreciation & Amortisation	$77.00K	$111.00K	$134.00K	$168.00K
Stock-Based Compensation	$7.93M	$7.10M	$8.53M	$8.86M
Investing Cash Flow	-$9.74M	$9.46M	-$264.00K	-$161.00K
Financing Cash Flow	$95.76M	$1.03M	$74.54M	$65.58M
Net Change in Cash	$20.88M	-$60.33M	-$10.49M	-$20.39M

IMUX Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$21.53M	$21.37M	$20.01M	$19.07M	$25.63M
Selling, General & Admin	$5.29M	$5.71M	$5.98M	$4.26M	$7.61M
Operating Expenses	$26.82M	$27.08M	$25.99M	$23.33M	$33.23M
Operating Income	-$26.82M	-$27.08M	-$25.99M	-$23.33M	-$33.23M
EBITDA	-$26.78M	-$27.04M	-$25.95M	-$23.29M	-$33.20M
Pretax Income	-$25.47M	-$26.82M	-$25.58M	-$19.30M	-$32.59M
Net Income	-$25.47M	-$26.82M	-$25.58M	-$19.30M	-$32.59M
Diluted EPS	-2.51	-2.00	-1.30	—	-1.08
Diluted Shares	10.13M	13.22M	19.39M	—	30.14M

IMUX Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$14.30M	$55.31M	$35.13M	$15.48M	$186.63M
Receivables	$1.71M	$594.00K	$177.00K	$4.12M	$354.00K
Current Assets	$18.98M	$59.84M	$39.27M	$22.87M	$188.76M
Total Assets	$20.52M	$61.43M	$40.70M	$24.05M	$189.74M
Current Liabilities	$25.59M	$27.31M	$30.08M	$30.62M	$38.36M
Total Debt	$975.00K	$979.00K	$792.00K	$577.00K	$421.00K
Total Liabilities	$25.80M	$27.52M	$30.20M	$30.73M	$38.51M
Retained Earnings	-$536.87M	-$563.69M	-$589.27M	-$608.57M	-$641.16M
Shareholders' Equity	-$5.29M	$33.91M	$10.50M	-$6.67M	$151.23M
Working Capital	-$6.62M	$32.53M	$9.19M	-$7.75M	$150.40M

IMUX Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$21.78M	-$24.61M	-$20.14M	-$19.28M	-$17.30M
Capital Expenditure	-$47.00K	-$36.00K	-$67.00K	-$11.00K	-$2.00K
Free Cash Flow	-$21.82M	-$24.64M	-$20.21M	-$19.29M	-$17.30M
Depreciation & Amortisation	$43.00K	$43.00K	$40.00K	$42.00K	$33.00K
Stock-Based Compensation	$2.04M	$1.90M	$3.61M	$1.31M	$4.47M
Investing Cash Flow	-$47.00K	-$36.00K	-$67.00K	-$11.00K	-$2.00K
Financing Cash Flow	$0.00	$65.52M	$0.00	$59.00K	$188.64M
Net Change in Cash	-$21.82M	$40.87M	-$20.21M	-$19.23M	$171.34M

Market Snapshot

About

Immunic, Inc. is a clinical-stage biopharmaceutical company developing selective oral therapies for chronic inflammatory and autoimmune diseases. The company's lead programs focus on treatments for ulcerative colitis, Crohn's disease, and primary sclerosing cholangitis, as well as relapsing-remitting multiple sclerosis. Immunic's pipeline is built around novel immunology-based mechanisms, including DHODH inhibition and inverse agonism of RORγt. The company aims to provide patients with oral treatment options that offer improved efficacy and safety profiles compared to existing therapies.